Natco Pharma Shares Surge Over 10% on Semaglutide Approval

Natco Pharma shares surged more than 10% after the company secured regulatory approval to launch the diabetes drug Semaglutide in India. The development strengthens its portfolio in the fast-growing anti-diabetes segment and is expected to open new revenue streams. Investors reacted positively to the announcement, anticipating stronger earnings momentum.Analysts believe successful commercialization could significantly enhance Natco Pharma’s competitive positioning in the domestic pharmaceutical market.